WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
15 April 2021
GSK to support manufacture of Novavax' COVID-19 vaccine
30 March 2021
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
24 February 2021
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
19 February 2021
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
04 February 2021
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
15 January 2021
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
17 December 2020
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
11 December 2020
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
12 November 2020
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
07 October 2020
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
GSK completes acquisition of Sierra Oncology
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
Research & Development
Researchers discover new leukemia-killing compounds
Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
Biomarkers found that could be drug targets against a deadly form of brain cancer
COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
Novel drug combo activates natural killer cell immunity to destroy cancer cells
Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
A new technology offers treatment for HIV infection through a single injection
Conferences & Events
New approach to treatment of deadly kidney cancer
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
SMi's 22nd Annual Pain Therapeutics Conference
SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
SMi's 3rd Annual AI in Drug Discovery Conference
Regulatory Affairs
FDA approves first systemic treatment for alopecia areata
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
FDA limits use of Janssen COVID-19 vaccine to certain individuals
EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
FDA approves first generic of Symbicort to treat asthma and COPD
You are here:
Home
GlaxoSmithKline